Improving outcomes & quality through collaboration

The Pediatric Cardiac Critical Care Consortium (PC⁴) aims to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease.

Support PC⁴

The Pediatric Cardiac Critical Care Consortium (PC⁴) aims to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease in North America and abroad. Formed in 2009 with National Institutes of Health funding, PC⁴ is a unique collaborative of leaders in pediatric cardiac critical care, cardiac surgery, and cardiology representing a diverse group of over 70 children’s hospitals across the globe caring for these vulnerable patients. The core pillars of collaborative quality improvement serve as the foundation for PC⁴. Using these pillars, we have been able to improve a variety of outcomes in these children, including the prevention of complications, such as cardiac arrest, and saving hundreds of children’s lives in our member centers.

News & Science

The latest clinical research published in the field pediatric cardiac critical care or referencing PC⁴ registry data

Early Neurodevelopmental Outcomes in Children With Congenital Heart Disease
Seed M, Ilardi D, Rofeberg V, Ortinau C, Goldberg C, Reichle G, Bush L, Elhoff J, Lisanti AJ, Butcher J, Rollins C, Van Bergen A, Peyvandi S, Bucholz E, Cox S, Hampton L, Sanz J, Monteiro S, Tewar S, Allen K, Lee C, Glotzbach K, Alexander N, Bear L, Anton C, Sananes R, Ly L, Boucher G, Wolfe K, Edwards L, Willen E, Tan A, Ortega C, Sood E, Sadhwani A, Plant KC, Quigley L, Pliego J, Valles E, Hines A, Wypij D and Miller T
Neurodevelopmental impairments are common in children with congenital heart disease.
Modified Ultrafiltration and Association With Outcomes After Neonatal Cardiac Surgery
Benscoter AL, Reagor JA, Timpa JG, Capone CC, Olshove V, Reichle G, Blinder JJ, Murphy LD, Lehenbauer DG, Alten JA, Zang H, Bacon MK, Jacobs JP, St Louis JD, Tabbutt S and
We sought to determine whether modified ultrafiltration (MUF) in the current era was associated with improved outcomes after neonatal cardiopulmonary bypass (CPB).
The Use of Inhaled Nitric Oxide After Pediatric Cardiac Surgery
Diddle JW, Patregnani J, Algaze CA, Banerjee M, Berger J, Reichle G, Louis JS, Sasaki J, Schumacher KR, Sinton J, Stigall W, Wolovits J, Zhang W and Tabbutt S
Inhaled nitric oxide (iNO) lowers pulmonary vascular resistance and improves pulmonary gas exchange. It has become a common therapy following pediatric cardiac surgery, but there are limited data on its current use or clinical impact in this population. This retrospective analysis reviewed all patients within the Pediatric Cardiac Critical Care Consortium (PC) clinical registry, representing 63 North American cardiac intensive care units (CICU), who underwent cardiac surgery from August 2014 to August 2023, to describe contemporary iNO use and its relationship to patient characteristics and outcomes. We also investigated the relationship between timing of iNO therapy for postoperative pulmonary hypertension (PH) and mortality. Of 63,582 non-neonatal patients admitted to the CICU following cardiac surgery, 12.2% received iNO, with 34.8% of those receiving it for PH. Of 17,792 neonates who underwent cardiac surgery, 26.6% received iNO, with 29.3% of those receiving it for PH. Single ventricle surgeries and heart transplant were the most common operations associated with iNO use. iNO use has increased over time, and utilization varies widely across centers, ranging from 0% to 65% of neonates, and 4% to 47% of infants. In a multivariable logistic regression model of patients who received iNO postoperatively for PH, initiation of therapy during the CICU stay, as compared to at CICU admission, was associated with increased mortality (odds ratio 1.54). Using contemporary multicenter registry data, we identify patient and operative characteristics associated with iNO use. Variations by center and by timing suggest opportunities to optimize use of the therapy.
Role of Home Monitoring in Reducing Disparities in the Interstage Mortality of Infants with Single Ventricle
El-Magharbel Y, Goldberg CS, Yu S, Valentini A, Uzark K, Romano JC, Fifer CG, Afton KM, Lowery R, Duimstra A and Balasubramanian S
To determine whether the interstage (between Norwood and stage 2 palliation) home monitoring program (IHMP) has reduced disparities in interstage survival and growth outcomes in patients with single-ventricle heart disease.
Machine-Learning Derived Individual Risk Prediction in Congenital Heart Surgery: Development and internal validation of risk prediction models for in-hospital mortality after congenital heart surgery using data from the Pediatric Cardiac Critical Care Consortium (PC4) registry
O'Byrne ML, Huang J, Faerber JA, Huang YV, Allen KY, Banerjee M, Graham EM, Griffis HM, Lasa JJ, Newburger JW, O'Connor MJ, Schumacher KR, Glatz AC, Pasquali SK and Gaynor JW
Machine learning (ML) methods may improve prediction of individual risk of mortality risk after congenital heart surgery (CHD) by identifying nonlinear relationships/novel combinations of variables. Improved risk discrimination may improve outcomes by optimizing resource allocation and patient surveillance.

Join PC⁴